7-b, a novel amonafide analogue, cause growth inhibition and apoptosis in Raji cells via a ROS-mediated mitochondrial pathway

Leukemia Research

Volumn 35, Issue 5, 2011, Pages 646-656

  Lin, Bing ^a   Chen, Zhuo ^a   Xu, Yufang ^a   Zhang, Huanying ^a   Liu, Jianwen ^a   Qian, Xuhong ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

7 b; Apoptosis; Cell cycle; Mitochondrial membrane potential; P21; Reactive oxygen species

Indexed keywords

6 (DODECYLAMINO) 2 [3 (4 METHYLPIPERAZIN 1 YL)PROPYL] 1H BENZO [DE]ISOQUINOLONE 1,3(2H) DIONE; 7 B; AMONAFIDE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 2; MYC PROTEIN; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA REPLICATION; DRUG STRUCTURE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR DYNAMICS; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BURKITT LYMPHOMA; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; HUMANS; MITOCHONDRIA; MODELS, BIOLOGICAL; NAPHTHALIMIDES; NECROSIS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 79954597853     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.01.029     Document Type: Article

References (50)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics. CA Cancer J Clin 2008, 58:71-96.
2. Avivi I., Robinson S., Goldstone A. Clinical use of rituximab in haematological malignancies. Br J Cancer 2003, 89:1389-1394.
3. Dalla-Favera R., Bregni M., Erikson J. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982, 79:7824-7827.
4. Taub R., Kirsch I., Morton C. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 1982, 79:7837-7841.
5. Avranitis C., Felsher D.W. Conditionally MYC: insights from novel transgenic models. J Cancer Lett 2005, 226:95-99.
6. Preudhomme C., Dervite I., Wattel E. Clinical significance of p53 mutation in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases. J Clin Oncol 1995, 13:812-820.
7. Bhaitia K., Fan S., Spangler G., Weintraub M., O'Connor P.M., Judde J.G., et al. A mutant 21 cyclin-dependent kinase inhibitor from a Burkitt's lymphoma. Adv Cancer Res 1995, 55:1431-1435.
8. Ko L.J, Prives C. p53: puzzle and paradigm. Genes Dev 1996, 10:1054-1072.
9. Reed J.C. Apoptosis-targeted therapies for cancer. Cancer Cell 2003, 3:17-22.
10. Brana M.F., Cacho M., Garcia M.A., de Pascual-Teresa B., Ramos A., Dominguez M.T., et al. New analogues of amonafide and elinafide, containing aromatic heterocycles: synthesis, antitumor activity, molecular modeling, and DNA binding properties. J Med Chem 2004, 47:1391-1399.
11. Antonini I., Santoni G., Lucciarini R., Amantini C., Sparapani S., Magnano A. Synthesis and biological evaluation of new asymmetrical bisintercalators as potential antitumor drugs. J Med Chem 2006, 49:7198-7207.
12. VanQuaquebeke E., Mahieu T., Dumont P., Dewelle J., Ribaucour F., Simon G., et al. 2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin5-yl}carbamoyl)acetamide (UNBS3157),a novel nonhematotoxic naphthalimide derivative with potent antitumor activity. J Med Chem 2007, 50:4122-4134.
13. Tumiatti V., Milelli A., Minarini A., Rosini M., Bolognesi M.L., Micco M., et al. Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone 4. Further investigation on the inner spacer. J Med Chem 2008, 51:7308-7312.
14. Li Z.G., Yang Q., Qian X.H. Novel thiazonaphthalimides as efficient antitumor and DNA photocleaving agents: effects of intercalation, side chains, and substituent groups. Biorg Med Chem 2005, 13:4864-4870.
15. Chen Z., Liang X., Zhang H., Xie H., Liu J., Xu Y., et al. A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis. J Med Chem 2010, 53:2589-2600.
16. Jane L., Watson, Richard Hill, Patrick WLee, Carman A., Giacomantonio, et al. Curcumin induces apoptosis in HCT-116 human colon cancer cells in a p21-independent manner. Exp Mol Pathol 2008, 84:230-233.
17. Raha S., Robinson B.H. Mitochondria, oxygen free radicals, and apoptosis. Am J Med Genet 2001, 106:62-70.
18. Pan J.S., Hong M.Z., Ren J.L. Reactive oxygen species: a double-edged sword in oncogenesis. World J Gastroenterol 2009, 15:1702-1707.
19. Starkov A.A. The role of mitochondria in reactive oxygen species metabolism and signaling. Ann NY Acad Sci 2008, 1147:37-52.
20. Robinson J.M. Reactive oxygen species in phagocytic leukocytes. Histochem Cell Biol 2008, 130:281-297.
21. Klaunig J.E., Kamendulis L.M. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 2004, 44:239-267.
22. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature 2000, 408:239-247.
23. Liang X., Wu A., Xu Y., Xu K., Liu J., Qian X. B1, a novel naphthalimide-based DNA intercalator, induces cell cycle arre-st and apoptosis in HeLa cells via p53 activation. Invest New Drugs 2010, [published online].
24. Verma M., Singh S.K., Bhushan S. In vitro cytotoxic potential of Polyalthia longifolia on human cancer cell lines and induction of apoptosis through mitochondrial-dependent pathway in HL-60 cells. Chem Biol Interact 2008, 171:45-56.
25. Wang J., Wu A., Xu Y., et al. M2-A induces apoptosis and G2-M arrest via inhibiting PI3K/Akt pathway in HL60 cells. Cancer Lett 2009, 283:193-202.
26. Wu A., Xu Y., Qian X., Wang J., Liu J. Novel naphthalimide derivatives as potential apoptosis-inducing agents: design, synthesis and biological evaluation. Eur J Med Chem 2009, 44:4674-4680.
27. Mitchell K.O., El-Deiry W.S. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-Otetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer Cells. Cell Growth Differ 1999, 10:223-230.
28. Li R., Waga S., Hannon G.J., Beach D., Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994, 371:534-537.
29. Waga S., Hannon G.J., Beach D., Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994, 369:574-578.
30. Chau M., Christensen J.L., Ajami A.M., Capizzi R.L. Amonafide, a topoisomerase II inhibitor, is unaffected by P-glycoprotein-mediated efflux. Leuk Res 2008, 32:465-473.
31. Burcu M., O'Loughlin K.L., Ford L.A., Baer M.R. Amonafide l-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia 2008, 22:2110-2115.
32. Steven L.A., Jonathan E.K., Ante S.L., John M.B., Robert L.C., Daniel R.B. Phase I trials of amonafide as monotherapy and in combination with cytarabine in patients with poor-risk acute myeloid leukemia. Leukemia Res 2010, 34:487-491.
33. Brana M.F., Ramos A. Naphthalimides as anti-cancer agents: synthesis and biological activity. Curr Med Chem 2001, 1:237-255.
34. Ratain M.J., Mick R., Berezin F., Janisch L., Schilsky R.L., Vogelzang N.J., et al. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res 1993, 53:2304-2308.
35. Offit K., Jhanwar S.C., Ladanyi M. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. Genes Chromosomes Cancer 1991, 3:189-201.
36. Maddika S., RaoAnde S., Soumya P., Paranjothy T., Weglarczyk K., Zuse A., et al. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007, 10:13-29.
37. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdkinte-racting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
38. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
39. Liu S., Bishop W.R., Liu M. Differential effects of cell cycle regulatory protein p21WAF1/Cip1 on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 2003, 6:183-195.
40. Gehen S.C., Vitiello P.F., Bambara R.A., Keng P.C., O'Reilly M.A. Downregulation of PCNA potentiates p21-mediated growth inhibition in response to hyperoxia. Am J Physiol Lung Cell Mol Physiol 2007, 292:716-724.
41. Buchholz M., Schatz A., Wagner M., Michl P., Linhart T., Adler G., et al. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. J EMBO 2006, 25:3714-3724.
42. Seoane J., Le H.V., Massagué J. Myc suppression of the p21 (Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 2002, 419:729-734.
43. Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991, 88:5413-5417.
44. Imamura J., Miyoshi I., Koeffler H.P. p53 in hematologic malignancies. Blood 1994, 84:2412-2421.
45. Hsu B., Marin M.C., El-Naggar A.K., Stephens L.C., Brisbay S., McDonnell T.J. Evidence that c-myc mediated apoptosis does not require wild-type p53 during lymphomagenesis. Oncogene 1995, 11:175-179.
46. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
47. Cadenas E., Davies K.J. Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med 2000, 29:222-230.
48. Crompton M., Barksby E., Johnson N., Capano M. Mitochondrial intermembrane junctional complexes and their involvement in cell death. Biochimie 2002, 84:143-152.
49. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 2003, 87:99-163.
50. McDonnell M.A., Wang D., Khan S.M., Vander Heiden M.G., Kelekar A. Caspase-9 is activated in a cytochrome c-independent manner early during TNFalpha induced apoptosis in murine cells. Cell Death Differ 2003, 10:1005-1015.